G1 Therapeutics (GTHX)
(Delayed Data from NSDQ)
$3.19 USD
+0.20 (6.69%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $3.19 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth C Momentum D VGM
Brokerage Reports
G1 Therapeutics [GTHX]
Reports for Purchase
Showing records 21 - 40 ( 356 total )
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Long-Term Survival Results From Phase 2 Trial of Cosela in mTNBC Patients to Be Presented at 2023 SABCS
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
3Q23 Results; Cosela Sales Lower Than Expected Due to the Continued Platinum Shortage
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Biotechnology- 2023 Small Molecule Precision Oncology Review and Outlook
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Real-World Cosela Data Presented at ASCO Quality Care Symposium; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Real World Data Provides Real Support for Cosela in ES-SCLC; TNBC Next
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
2Q23 Results; Platinum-Based Chemotherapy Shortage Hampers Sales; Important Data Readouts Expected in 1Q24
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Trilaciclib + Trodelvy Data on Par; Looking Towards PRESERVE-2 Main Event
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Preliminary Results From Phase 2 Study of Cosela in Combination With Trodelvy for TNBC Patients
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
1Q23 Results; Cosela Sales Continue to Rise; Cash Runway Extended Through Important Data Readouts
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
4Q22 Results; Cosela Sales Picking Up; Data From Two Studies Expected Later This Year
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E